Posted: February 17, 2008

Roche Leads Biotechnology Industry with an Unprecedented Growth of Nearly 100%

(Nanowerk News) Roche Holding Ltd remains the leader for the Biotechnology Scorecard, with an unprecedented Science Strength (SS™) that grew by almost 100% this past quarter. Their lead is primarily due to majority owned subsidiary and biotech, Genentech, who account for approximately 80% of the patents represented.
Geron Corp, known for stem cell research has soared into the top 10 moving up 7 spots to sit in 5th position with an increase in SS™ of 77%. There are two other newcomers to the top 10, one of which is Nanosphere Inc, who is bringing the combination of nanotechnology and molecular diagnostics into the marketplace.
The other is little known Ultra Biotech Ltd which utilizes electromagnetic energy for culturing biotechnology compositions.
Eight of the top 10 companies have above average Research Intensity (RI™), which measures the degree of scientific referencing for their most recent patenting compared to others in the industry. The largest increases in Research Intensity™ this quarter came from 1st and 2nd ranked, Roche (52%) and Invitrogen (23%), while newcomers Geron and Nanosphere have the highest scores among the top 10 of 3.43 and 3.29 respectively.
They are both referencing well known publications such as Proceedings of the National Academy of Science and The Journal of Biological Chemistry; however Nanosphere is also highly referencing the interdisciplinary journal, Langmuir, further showing its differentiation in the marketplace. Another company who is highly referencing Langmuir is Affymetrix, ranked 18th (not charted) who pioneered the use of semiconductors and combinatorial chemistry for biotechnology use.
Despite dropping a spot each this quarter, both Isis Pharmaceuticals Inc and Biogen Idec Inc have RI™ scores twice the industry average.
This industry is smaller in terms of patent volume, where the average yearly patents granted is 24. The three largest patent holders are Roche, Monsanto Co and Amgen Inc, with each of them separated by 100 or more patents; however the rest of the companies have 50 or fewer patents issued per year. Among the top 10, Geron had the largest gain of 37.5%, but was only reflective of a gain of 3 patents due to its small size, while Human Genome Sciences saw the biggest decrease by 30%. The companies within the industry had an overall growth in patenting by 5.9%.
Only 3 of the top 10 had an increase in Industry Impact™ (II™) this quarter and just 4 have impacts above the industry average. This is not a surprising trend as this indicator measures the recent impact of citations to current patenting rather than all citations received over time, where influential patents in this industry may not show a citation impact for 10 or more years after issuance.
Newcomer Geron is atop all the indicators this quarter, increasing its II™ score by 83% this quarter for a score of 1.7, or a 70% higher citation frequency than the industry. Ultra Biotech and Nanosphere both have very high II™ scores of 10.6 and 6.1 respectively. However, their II™ scores are a result of a high degree of self-citations, commonly seen in very new and unique technologies, and in the case of Ultra Biotech it is 100% self citations.
It is yet to be known whether these technologies will make an impact on the industry, from either an external citation perspective or market acceptance; however they are both building upon core science enough to warrant a top 10 spot.
The average Innovation Cycle Time (ICT™) for Biotechnology this quarter was 9.4 years, with 6 of the top 10 having shorter cycle times. Newcomer Nanosphere has the shortest of 7.2 years, while Roche is not far behind at 7.4 years. Biogen Idec saw a slight decrease in its cycle time this quarter, while Isis Pharmaceuticals added 1 years to its cycle time. Bioengineering seed giant, Monsanto has the longest ICT™ at 11.9 years, which may be reflective of the absence of newer innovations for this type of technology.
The Biotechnology industry includes companies that use living organisms or parts of living organisms to produce products primarily related to food, medicine and diagnostics. Companies are involved in research and development in various fields including genetics, bacteriology, biochemical engineering, microbiology, virology and protein engineering.
There are a total of 66 companies represented in the Biotechnology Industry Patent Scorecard™, 10 are also represented in other scorecard industries of which 6 are also in the Pharmaceutical scorecard for producing synthetic pharmaceuticals as well. This is a trend that is becoming more common where the line between these two industries is becoming blurred with the ever-increasing Biopharmaceutical industry.
Seven of the companies in the top 10 are primarily targeting diseases with patent holdings pertaining to proteins, cellular biology, RNA, and monoclonal antibodies for drug development. The remaining companies are involved in genomic testing, diagnostic assays, nucleic acid purification and bioengineered crops.
Founded in 1968 as a patent analytics and research institution, The Patent Board is the leading independent provider of best practices research, tools and metrics for patent analysis and intellectual property investment. The Patent Board tracks and analyzes innovation, movement, and the business value of patent assets across every industry on a global basis.
Source: ag-IP-news
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: